Pneumonia immunization in older adults: Review of vaccine effectiveness and strategies

Clinical Interventions in Aging

Volumn 7, Issue , 2012, Pages 453-461

  Assaad, Usama ^b   El Masri, Ibrahim ^b   Porhomayon, Jahan ^a,b   El Solh, Ali A ^a,b  

^a VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Influenza vaccine; Older adults; Pneumococcal vaccine; Pneumonia; Vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; B LYMPHOCYTE; BIOAVAILABILITY; COMMUNITY CARE; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE POLICY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; LONG TERM CARE; LYMPHOCYTE DEPLETION; MEMORY CELL; MIXED INFECTION; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; OPSONIZATION; PNEUMOCOCCAL INFECTION; PNEUMONIA; PROTEIN MODIFICATION; REVACCINATION; REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE; UNITED STATES; VALIDITY; VIRUS VIRULENCE;

AGE FACTORS; AGED; AGED, 80 AND OVER; HUMANS; INFLUENZA VACCINES; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA; VACCINES, CONJUGATE; VACCINES, INACTIVATED;

EID: 84872312605     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S29675     Document Type: Review

References (105)

1. Silverman ME, Murray TJ, Bryan CS. The Quotable Osler. Philadelphia: American College of Physicians; 1998:139.
2. Heron M, Tejada-Vera B. Deaths: leading causes for 2005. Natl Vital Stat Rep. 2009;58(8):1-97.
3. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005;165(3):265-272.
4. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb Mortal Wkly Rep. 2010;59(33):1057-1062.
5. Beigel JH. Influenza. Crit Care Med. 2008;36(9):2660-2666.
6. Thomas CP, Ryan M, Chapman JD, etal. Incidence and cost of pneumonia in Medicare beneficiaries. Chest. Epub March 8, 2012.
7. Fedson DS, Musher DM. Pneumococcal polysaccharide vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia: Saunders; 2003:529-588.
8. Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis. 1996;173(2):387-393.
9. Lai CC, Lee LN, Yu CJ, etal. Antibody responses to pneumococcal polysaccharide vaccine in Taiwanese patients with chronic obstructive pulmonary disease. J Formos Med Assoc. 2007;106(3):196-203.
10. Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine. 2008;26(43):5521-5526.
11. Rubins JB, Puri AK, Loch J, etal. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis. 1998;178(2):431-440.
12. Romero-Steiner S, Musher DM, Cetron MS, etal. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 1999;29(2):281-288.
13. Ortqvist A. Pneumococcal vaccination: current and future issues. Eur Respir J. 2001;18(1):184-195.
14. Musher DM, Manof SB, Liss C, etal. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010;201(4):516-524.
15. Manoff SB, Liss C, Caulfield MJ, etal. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 or = years. J Infect Dis. 2010;201(4):525-533.
16. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis. 2007;7(9):597-606.
17. de Roux A, Schmole-Thoma B, Siber GR, etal. Comparison of conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46(7):1015-1023.
18. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;(1):CD000422.
19. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med. 1984;101(3):325-330.
20. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med. 1988;108(5):653-657.
21. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol. 2004;19(4):353-363.
22. Kaufman P. Pneumonia in old age; active immunization against pneumonia with pneumonococcus polysaccharide; results of a six year study. Arch Intern Med. 1947;79(5):518-531.
23. Gaillat J, Zmirou D, Mallaret MR, etal. Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions. Rev Epidemiol Sante Publique. 1985;33(6):437-444. French.
24. Honkanen PO, Keistinen T, Miettinen L, etal. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine. 1999;17(20-21):2493-2500.
25. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, etal. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65study. Clin Infect Dis. 2006;43(7):860-868.
26. Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, etal. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine. 2009;27(10):1504-1510.
27. Jackson LA, Neuzil KM, Yu O, etal. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348(18): 1747-1755.
28. Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis. 2010;51(1): 15-22.
29. Riley ID, Lehmann D, Alpers MP, Marshall TF, Gratten H, Smith D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet. 1986;2(8512):877-881.
30. Wagner C, Popp W, Posch M, Vlasich C, Rosenberger-Spitzy A. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study. Gerontology. 2003;49(4): 246-250.
31. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol. 2004;19(4): 365-375.
32. Simberkoff MS, Cross AP, Al-Ibrahim M, etal. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;315(21):1318-1327.
33. Austrian R. Surveillance of Pneumococcal Infection for Field Trials of Polyvalent Pneumococcal Vaccines. Bethesda: National Institutes of Health; 1980.
34. Kawakami K, Ohkusa Y, Kuroki R, etal. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine. 2010; 28(43):7063-7069.
35. Maruyama T, Taguchi O, Niederman MS, etal. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010;340:c1004.
36. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med. 1997;103(4):281-290.
37. Ortqvist A, Hedlund J, Burman LA, etal. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 1998;351(9100):399-403.
38. Alfageme I, Vazquez R, Reyes N, etal. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006;61(3): 189-195.
39. Hirschmann JV, Lipsky BA. The pneumococcal vaccine after 15 years of use. Arch Intern Med. 1994;154(4):373-377.
40. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis. 2008;47(10): 1328-1338.
41. Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2003;(4): CD000422.
42. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180(1):48-58.
43. Arguedas A, Soley C, Abdelnour A. Prevenar experience. Vaccine. 2011;29 Suppl 3:C26-C34.
44. Dagan R, Gradstein S, Belmaker I, etal. An outbreak of Streptococcus pneumoniae serotype 1in a closed community in southern Israel. Clin Infect Dis. 2000;30(2):319-321.
45. Romney MG, Hull MW, Gustafson R, etal. Large community outbreak of Streptococcus pneumoniae serotype 5invasive infection in an impoverished, urban population. Clin Infect Dis. 2008;47(6): 768-774.
46. Hausdorff WP. The roles of pneumococcal serotypes 1 and 5in paediatric invasive disease. Vaccine. 2007;25(13):2406-2412.
47. Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]). Philadelphia, PA: Wyeth Pharmaceuticals; 2011.
48. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar 13. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm279680.pdf. Accessed October 12, 2012.
49. Centers for Disease Control and Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep. 2012;61(21):394-395.
50. Hak E, Grobbee DE, Sanders EA, etal. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008;66(9):378-383.
51. Pilishvili T, Lexau C, Farley MM, etal. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41.
52. Choi YH, Jit M, Flasche S, Gay N, Miller E. Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales. PloS One. 2012;7(7): e39927.
53. Rubin JL, McGarry LJ, Strutton DR, etal. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28(48):7634-7643.
54. Stuart WH, Dull HB, Newton LH, McQueen JL, Schiff ER. Evaluation of monovalent influenza vaccine in a retirement community during the epidemic of 1965-1966. JAMA. 1969;209(2):232-238.
55. Burney LE. Influenza immunization: statement. Public Health Rep. 1960;75(10):944.
56. Long PH. Recommendations for influenza immunization and control: 1964-1965. Med Times. 1964;92:1203-1205.
57. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272(21):1661-1665.
58. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24(8): 1159-1169.
59. Allsup S, Haycox A, Regan M, Gosney M. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine. 2004;23(5):639-645.
60. Praditsuwan R, Assantachai P, Wasi C, Puthavatana P, Kositanont U. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. J Med Assoc Thai. 2005;88(2): 256-264.
61. Treanor JD. Influenza-the goal of control. N Engl J Med. 2007;357(14):1439-1441.
62. Nichol KL. Challenges in evaluating influenza vaccine effectiveness and the mortality benefits controversy. Vaccine. 2009;27(45): 6305-6311.
63. Nordin J, Mullooly J, Poblete S, etal. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis. 2001;184(6):665-670.
64. Hak E, Wei F, Grobbee DE, Nichol KL. A nested case-control study of influenza vaccination was a cost-effective alternative to a full cohort analysis. J Clin Epidemiol. 2004;57(9):875-880.
65. de Diego C, Vila-Corcoles A, Ochoa O, etal. Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. Eur Heart J. 2009;30(2):209-216.
66. Campitelli MA, Rosella LC, Stukel TA, Kwong JC. Influenza vaccination and all-cause mortality in community-dwelling elderly in Ontario, Canada, a cohort study. Vaccine. 2010;29(2):240-246.
67. Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol. 2001;154(2):155-160.
68. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357(14):1373-1381.
69. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine. 2002;20(13-14):1831-1836.
70. Rivetti D, Jefferson T, Thomas R, etal. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2006;(3): CD004876.
71. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366(9492):1165-1174.
72. Fiore AE, Shay DK, Broder K, etal. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57(RR-7):1-60.
73. Deans GD, Stiver HG, McElhaney JE. Influenza vaccines provide diminished protection but are cost-saving in older adults. J Intern Med. 2010;267(2):220-227.
74. Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med. 2006;31(1):72-79.
75. Jefferson T. Influenza vaccination: policy versus evidence. BMJ. 2006;333(7574):912-915.
76. Fireman B, Lee J, Lewis N, Bembom O, van der Laan M, Baxter R. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol. 2009;170(5):650-656.
77. Simonsen L, Viboud C, Taylor RJ, Miller MA, Jackson L. Influenza vaccination and mortality benefits: new insights, new opportunities. Vaccine. 2009;27(45):6300-6304.
78. Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, Jackson LA. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet. 2008;372(9636):398-405.
79. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007;7(10):658-666.
80. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;(7):CD001269.
81. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis. 2008;197(4):490-502.
82. Feng J, Gulati U, Zhang X, etal. Antibody quantity versus quality after influenza vaccination. Vaccine. 2009;27(45):6358-6362.
83. Ansaldi F, Bacilieri S, Durando P, etal. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine. 2008;26(12):1525-1529.
84. Ansaldi F, Zancolli M, Durando P, etal. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59-and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine. 2010;28(25): 4123-4129.
85. Panda A, Qian F, Mohanty S, etal. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol. 2010;184(5):2518-2527.
86. Nuzum J, Pilote I, Stangl F, Bonar B. Pandemic influenza and pneumonia in a large civilian hospital. JAMA. 1918;71:1562-1565.
87. Schwarzmann SW, Adler JL, Sullivan RJ Jr, Marine WM. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med. 1971;127(6):1037-1041.
88. Palacios G, Hornig M, Cisterna D, et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PloS One. 2009;4(12):e8540.
89. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006;19(3):571-582.
90. Diavatopoulos DA, Short KR, Price JT, etal. Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. FASEB J. 2010;24(6):1789-1798.
91. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7): 962-970.
92. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J. 2004;23(3):363-368.
93. Weaver M, Krieger J, Castorina J, Walls M, Ciske S. Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines. Arch Intern Med. 2001;161(1):111-120.
94. Cai L, Uchiyama H, Yanagisawa S, Kamae I. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan. Kobe J Med Sci. 2006;52(3-4):97-109.
95. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med. 2010;363(21):2036-2044.
96. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med. 2010;16(12): 1389-1391.
97. Giefing C, Meinke AL, Hanner M, etal. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med. 2008;205(1):117-131.
98. Lu YJ, Leite L, Goncalves VM, etal. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine. 2010;28(47):7468-7475.
99. Cate TR, Rayford Y, Nino D, etal. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine. 2010;28(9):2076-2079.
100. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200(2):172-180.
101. De Villiers PJ, Steele AD, Hiemstra LA, etal. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine. 2009;28(1):228-234.
102. Huckriede A, Bungener L, Stegmann T, etal. The virosome concept for influenza vaccines. Vaccine. 2005;23 Suppl 1:S26-S38.
103. Bernstein DI, Edwards KM, Dekker CL, etal. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis. 2008;197(5):667-675.
104. Chu DW, Hwang SJ, Lim FS, etal. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine. 2009;27(52): 7428-7435.
105. Jha AK, Wright SM, Perlin JB. Performance measures, vaccinations, and pneumonia rates among high-risk patients in Veterans Administration health care. Am J Public Health. 2007;97(12):2167-2172.